CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSCLINICAL TRIALSPUBLICATIONSArpan A. Patel, M.D.Contact InformationPhone NumbersAppointment: (585) 275-5823Administrative: (585) 275-9319Fax: (585) 273-1042A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentAccepting New PatientsLocationsWilmot Cancer Institute Oncology601 Elmwood Ave, Ste GRochester, NY 14642-0001Oncology: (585) 275-5823Wilmot Cancer Institute Oncology601 Elmwood AveRochester, NY 14642-0001Oncology: (585) 275-5823Faculty AppointmentsAssistant Professor - Department of Medicine , Hematology/Oncology (SMD) Patient Care SettingCancerBiographyThe diagnosis of cancer affects not only a patient, but their family and friends as well. I chose the field of oncology to help those through this very difficult situation with compassion, respect, and dignity. As health care is becoming more complex, it is important not to lose focus on patient distress, financial toxicities, and quality of life. Working with a multidisciplinary team we will provide the best quality of care and patient-centered approach for you and your loved ones. My primary clinical focus is lung cancer (including small cell, non-small cell lung cancer, and mesothelioma), & head and neck cancer. We are always addressing unmet clinical needs with clinical research trials in order to provide cutting edge medical treatments and push the field of oncology in order to better serve our patients. My research interests include thoracic oncology, quality improvement, patient distress, and education.Professional BackgroundMy roots are in Upstate NY - specifically New Hartford NY. I completed my Internal Medicine training with SUNY Upstate Medical University in Syracuse NY. I stayed on as Chief Resident for an additional year. Thereafter my fellowship training in Hematology Oncology was completed with the University of Florida in Gainesville, FL.ResearchMy research interests include Thoracic-Oncology, Quality Improvement, Financial Toxicity, Patient Distress, and Education.CredentialsSpecialtiesHematology - American Board of Internal MedicineInternal Medicine - American Board of Internal MedicineMedical Oncology - American Board of Internal MedicineEducation2012MD | University of LubinPost-doctoral Training & Residency07/01/2016 - 06/30/2019Fellowship in Hematology/Oncology at University of Florida College of Medicine07/01/2013 - 06/30/2016Residency in Internal Medicine at Upstate Medical University07/01/2012 - 06/30/2013Internship in Internal Medicine at Upstate Medical UniversityVIEW ALL expand_moreAwards2019Chief Fellow AwardSponsor: University of FloridaLocation: Gainesville, FL2019Craig S Kitchens Award for Peer Mentorship, Education, and LeadershipSponsor: University of FloridaLocation: Gainesville, FL2018Induction into the University of Florida Chapman Chapter of the Gold Humanism Honor Society (GHHS)Sponsor: University of FloridaLocation: Gainesville, FL2018Housestaff Distinguished Hero of Quality AwardSponsor: University of FloridaLocation: Gainesville, FL2015David B Duggan MD AwardSponsor: SUNY Upstate Medical UniversityLocation: Syracuse, NY2015Alpha Omega Gamma Chapter Excellence in Teaching AwardSponsor: SUNY Upstate Medical UniversityLocation: Syracuse, NY2012Intern Teaching AwardSponsor: SUNY Upstate Medical UniversityLocation: Syracuse, NY2012Induction into Arnold Gold Humanism Honor Society of SUNY Upstate Medical UniversitySponsor: SUNY Upstate Medical UniversityLocation: Syracuse, NYVIEW ALL expand_moreClinical TrialsRandomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLCLead Researcher: Arpan A Patel This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab. View Study Details PublicationsJournal Articles5/2019Gopalan PK, Patel A, Bodner S. "Improving Documentation of Distress in Veteran Patients for Hematology/Oncology Clinics." Journal of oncology practice. 2019 May 0; 15(5):e475-e479. Epub 2019 Apr 09. 10/2018Dhamoon AS, Kosters M, Panebianco L, Patel A, Gudlavalleti A, Krowl L. "A pilot study to standardize and peer-review shift handoffs in an academic internal medicine residency program: The DOCFISH method." Medicine.. 2018 Oct 0; 97(41):e12798. 8/30/2018Markham MJ, Nwosu-Lheme A, Lutfi F, Ali A, Patel A. "An Interactive Multimodality Curriculum Teaching Medicine Residents About Oncologic Documentation and Billing." MedEdPORTAL : the journal of teaching and learning resources.. 2018 Aug 30; 14:10746. Epub 2018 Aug 30. VIEW ALL PUBLICATIONSClose WindowSchedule an appointment with Arpan A. Patel, M.D.Please answer the following questions to help us find the right appointment for you.Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.Have you seen this provider in the last 2 years?YesNoExisting Patient Schedule or request a follow up appointment online through MyChart. If you do not have a MyChart account, please close this window and call the appointment phone number. Arpan A. Patel, M.D. is currently scheduling for the following appointment type(s): Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.